PD-L1 CPS est le biomarqueur prédictif primaire pour le pembrolizumab dans les H récurrents/métastatiques...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-PDL1-CPS-HNSCC |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-07 | actionability review required |
| Maladies | DIS-HNSCC |
| Sources | SRC-ESMO-HNSCC-2020 SRC-NCCN-HNSCC-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-PDL1-CPS |
|---|---|
| Maladie | DIS-HNSCC |
| Niveau ESCAT | IA |
| Combinaisons recommandées | pembrolizumab monotherapy (CPS≥20 1L per SRC-NCCN-HNSCC-2025, SRC-ESMO-HNSCC-2020), pembrolizumab + platinum + 5-FU (CPS≥1 1L per SRC-NCCN-HNSCC-2025) |
| Résumé des faits | PD-L1 CPS is the primary predictive biomarker for pembrolizumab in recurrent/metastatic HNSCC (KEYNOTE-048). Two threshold-stratified eligibility bands: CPS ≥1 — pembrolizumab + platinum + 5-FU 1L (superior to EXTREME regimen in CPS≥1 population); CPS ≥20 — pembrolizumab monotherapy 1L (preferred over chemo in high-expressors; mOS 14.9 mo). Both are FDA-approved and NCCN/ESMO Category 1 recommendations. Testing by IHC 22C3. Threshold selection is performed by the algorithm layer (ALGO-HNSCC-RM-1L); this BMA entry surfaces ESCAT tier context for tumor-board discussion only. |
Notes
Variant_qualifier null — dual-threshold gating (CPS≥1 for combo, CPS≥20 for mono) is enforced by the algorithm/indication layer, not this BMA cell. KEYNOTE-048 source stub not yet ingested; citing NCCN/ESMO as proxies.
Utilisé par
No reverse references found in the YAML corpus.